These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 11785853

  • 41. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia.
    Wu JH, Howard DH, McGowan JE, Frau LM, Dai WS.
    Clin Ther; 2004 Dec; 26(12):2153-62. PubMed ID: 15823779
    [Abstract] [Full Text] [Related]

  • 42. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
    Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group.
    J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
    [Abstract] [Full Text] [Related]

  • 43. Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance.
    Dunbar LM.
    Am J Med Sci; 2003 Dec; 326(6):360-8. PubMed ID: 14671500
    [Abstract] [Full Text] [Related]

  • 44. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 45. Beta-lactam antibiotics in lower respiratory tract infections.
    Schreiner A.
    Scand J Infect Dis Suppl; 1984 May; 42():129-34. PubMed ID: 6597558
    [Abstract] [Full Text] [Related]

  • 46. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E, Garau J.
    Respiration; 2005 May; 72(6):561-71. PubMed ID: 16354997
    [Abstract] [Full Text] [Related]

  • 47. Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections.
    Nicolau DP.
    Am J Manag Care; 2000 Dec; 6(23 Suppl):S1202-10. PubMed ID: 11187444
    [Abstract] [Full Text] [Related]

  • 48. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN, Yu VL.
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [Abstract] [Full Text] [Related]

  • 49. Clarithromycin in the management of community-acquired pneumonia.
    McCarty JM.
    Clin Ther; 2000 Mar; 22(3):281-94; discussion 265. PubMed ID: 10963284
    [Abstract] [Full Text] [Related]

  • 50. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C.
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [Abstract] [Full Text] [Related]

  • 51. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D, Zhanel G, Hoban D.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [Abstract] [Full Text] [Related]

  • 52. How short can courses be in lower respiratory tract infections?
    Siegel R.
    J Int Med Res; 2000 Sep; 28 Suppl 1():37A-47A. PubMed ID: 11092228
    [Abstract] [Full Text] [Related]

  • 53. Diagnostic testing to establish a microbial cause is helpful in the management of community-acquired pneumonia.
    Skerrett SJ.
    Semin Respir Infect; 1997 Dec; 12(4):308-21. PubMed ID: 9436958
    [Abstract] [Full Text] [Related]

  • 54. Geminofloxacin for the management of community-acquired respiratory tract infections.
    Blondeau JM, Tillotson G, Deangelis J.
    J Chemother; 2006 Dec; 18(6):582-8. PubMed ID: 17267335
    [Abstract] [Full Text] [Related]

  • 55. Antibiotic resistance in community-acquired respiratory tract infections: current issues.
    Spach DH, Black D.
    Ann Allergy Asthma Immunol; 1998 Oct; 81(4):293-302; quiz 302-3. PubMed ID: 9809491
    [Abstract] [Full Text] [Related]

  • 56. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL, Rico G, Rodríguez-Parga D, Mascareño A, Rangel-Frausto S.
    Adv Ther; 2000 Oct; 17(6):263-71. PubMed ID: 11317829
    [Abstract] [Full Text] [Related]

  • 57. [Management of community-acquired lower respiratory infections. Management in the hospital].
    Chidiac C.
    Rev Mal Respir; 1999 Jan; 16 Suppl 3():S11-2. PubMed ID: 10088221
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
    Momméja-Marin H, Carbon C.
    Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400
    [Abstract] [Full Text] [Related]

  • 60. Antibiotics for community-acquired pneumonia.
    Dryden M, Hand K, Davey P, BSAC Council.
    J Antimicrob Chemother; 2009 Dec; 64(6):1123-5. PubMed ID: 19820250
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.